Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...
eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
Medscape

Allogeneic CD19 CAR-NK Cell Therapy May Be a New Chapter in Refractory SLE Care

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

CRISPR Breakthrough Could Rewrite Future of Genetic Disease Treatment

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...
TMCnet

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa is composed of IDS fused to Denali’s TransportVehicle™ platform and is engineered to cross the blood-brain barrier, aiming to treat neurological manifestations of MPS II in addition ...